Form 4 KALOBIOS PHARMACEUTICALS For: Nov 16 Filed by: Shkreli Martin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street
November 19, 2015 1:36 PM ESTThe stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.
$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.
You see, just... More
Anthion Partners II Buys ~700K Shares of KaloBios Pharma (KBIO), Adding to Madness
November 18, 2015 5:39 PM ESTIn addition to the Martin Shkreli buys on KaloBios Pharma (NASDAQ: KBIO) disclosed after the close, Anthion Partners II disclosed it bought 713,726 shares on 11/16 at $1.26-$1.76. Shares are up 700% after-hours.
... MoreWith Shkreli Spike, KaloBios Pharma (KBIO) May Be Overvalued by a Factor of 4
November 18, 2015 4:57 PM ESTThe upside being seen in KaloBios Pharma (NASDAQ: KBIO) after the close (400%+) after Martin Shkreli... More
KaloBios Pharma (KBIO) Pops on Shkreli Insider Buy
November 18, 2015 4:25 PM ESTKaloBios Pharma (NASDAQ: KBIO) ripping higher as Martin Shkreli purchased shares.
Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.
On November 13, 2015, KaloBios announced that it will wind down its operations and that it has engaged the Brenner... More
